drugset
Drugs / H3B-8800
last change Jun 2025 re-read 3 minutes ago

H3B-8800

also known as RVT-2001

targets SF3B1

Developed for
acute myeloid leukemia · chronic myelomonocytic leukemia · myelodysplastic syndrome
Investigated by
Hemavant Sciences GmbH

Trials 1

today NCT02841540 · Ph 1
20172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT02841540 Oct 2016 → Feb 2024 acute myeloid leukemia, chronic myelomonocytic leukemia, myelodysplastic syndrome Hemavant Sciences GmbH Terminated Missed primary

Press releases naming this drug 1 release

DateIssuerRelease
2022-01-06 Eisai Inc. EISAI ENTERS INTO EXCLUSIVE LICENSING AGREEMENT WITH ROIVANT CONCERNING INVESTIGATIONAL ANTICANCER AGENT H3B-8800,A SPLICING MODULATOR eisai.com ↗

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as H3B-8800 ClinicalTrials.gov intervention name — accepted as the source's own label NCT02841540 ↗
Known as RVT-2001 “A Phase 1, an Open-label, Multicenter Phase 1 Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Splicing Modulator H3B-8800 (RVT-2001) for Subjects With...” NCT02841540 ↗
Route Oral “H3B-8800 (RVT-2001) orally at specified doses and schedules.” NCT02841540 ↗
Target SF3B1 “oral SF3B1 modulator H3B‑8800” PMID 40651101 ↗ Jun 2025